Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26 Mln
Revenue (TTM)
$11 Mln
Net Profit (TTM)
$0 Mln
ROE
-29.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.3
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-6.2
Face value
--
Shares outstanding
10,462,200
CFO
$-343.27 Mln
EBITDA
$-355.11 Mln
Net Profit
$-454.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -24.8 | 13.3 | -22.0 | -72.0 | -51.8 | -37.6 | -39.0 |
|
BSE Sensex
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -75.7 | 15.9 | -88.4 | -41.9 | 381.8 | 146.4 | -80.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
|
2.3 | 25.8 | 11.2 | -42.1 | -375.5 | -- | -- | 4.3 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.7 | 3.9 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.7 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.6 | |
| 25.4 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase... inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421 Read more
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Curis Inc (CRIS) stood at $ 59 Mln as on 31-Mar-25
The share price of Curis Inc (CRIS) is $2.30 (NASDAQ) as of 18-Jun-2025 16:15 EDT. Curis Inc (CRIS) has given a return of -51.85% in the last 3 years.
Curis Inc (CRIS) has a market capitalisation of $ 26 Mln as on 17-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Curis Inc (CRIS) is 4.32 times as on 17-Jun-2025, a 57% premium to its peers’ median range of 2.75 times.
Since, TTM earnings of Curis Inc (CRIS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Curis Inc (CRIS) and enter the required number of quantities and click on buy to purchase the shares of Curis Inc (CRIS).
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421
The CEO & director of Mr. James E. Dentzer. is Curis Inc (CRIS), and CFO & Sr. VP is Mr. James E. Dentzer.
There is no promoter pledging in Curis Inc (CRIS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Curis Inc. (CRIS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-375.51
|
|
Net Margin(%)
|
-376.08
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Curis Inc (CRIS) was $0 Mln.
$-0.06
(
